Physician

Adam Cherry, OD

According to 2025 Medicare claims, Adam Cherry, OD (NPI: 1518116268) practices optometrist in the West Palm Beach-Boca Raton-Delray Beach, FL market, with the plurality of this provider's patient population coming from Palm Beach, FL. This provider's primary affiliated billing organization is MAHALO ENTERPRISES CORPORATION (NPI: 1043535404) and primary practice location at 33463-3008.

Cherry's data goes back to 2015 and runs through 2024. For example, in 2023, this provider had 27 traditional Medicare patients, billed 32 HCPCS/CPT codes, and received $2,145 in Medicare payments. 2024 Part D data shows 44 prescription claims across 17 beneficiaries totaling $2,473 in drug costs, led by Latanoprost (Latanoprost). Open Payments data shows 1 records totaling $26. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $4,651 and ending at $2,145. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $2,042 to $2,473. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	45	48	$4,651
2020	33	37	$3,566
2021	31	36	$3,186
2022	41	54	$4,861
2023	27	32	$2,145
2024	N/R	N/R	N/R

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	12	17	$2,042
2021	N/R	25	$1,405
2022	19	36	$1,602
2023	15	27	$6,490
2024	17	44	$2,473

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

No connected Part B code-level records for 2024.

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Latanoprost	Latanoprost	21	657	$158

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$26	Astellas Pharma US Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam Cherry, OD?

Tedicare shows public-source Medicare data for Adam Cherry, OD (NPI 1518116268), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam Cherry, OD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adam Cherry, OD?

Adam Cherry, OD is linked to MAHALO ENTERPRISES CORPORATION (billing NPI 1043535404) in the available physician profile data.

Does Adam Cherry, OD have Open Payments data?

Adam Cherry, OD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.